Advances in adverse cardiovascular events in patients with anemia and atrial fibrillation
ZHANG Zhu-xin
YAO Yan
Abstract：Anemia means a decrease in hemoglobin concentration or hematocrit value,affecting a quarter of the world's population.Anemia is common in the older population and people with other chronic diseases,such as heart failure and diabetes.Atrial fibrillation(AF)is the most common arrhythmia.The risk of developing AF increases with age,with a global prevalence of approximately 0.5％,which will increase significantly in the next 50 years as the population ages.AF increases the risk of cardiac thromboembolism and death.While oral anticoagulants reduces the risk of thromboembolic events in patients with AF,it is at the cost of increased bleeding risk.Anemia has now been identified as a predictor of bleeding complications in anticoagulated patients with AF and as a component of bleeding risk assessment models such as the ORBIT score.In heart failure and coronary artery disease as well as in the elderly,anemia is likewise considered a predictor of thromboembolic events.In addition,anemia has been associated with a poorer prognosis and/or higher mortality in patients with various cardiovascular diseases,such as coronary artery disease after percutaneous coronary intervention and chronic heart failure.Atrial fibrillation is equally prevalent in these populations,and as a chronic disease,also often coexists with anemia.However,the prevalence of anemia in patients with atrial fibrillation and its association with adverse cardiovascular events have not been well described so far.This review focuses on the impact of anemia on clinical adverse outcomes of thromboembolic events,bleeding,and death in patients with atrial fibrillation.
Keywords：Atrial fibrillationAnemiaIron-deficiencyAdverse outcomes
Publication Date：2024-06-10
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：6( 522-527 )